DOBUTamine Injection USP Rx ONLY

Manufacturer
Hikma Pharmaceuticals USA Inc.
Effective date
2024-07-02
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
6
Source
full-release
Hydrated at
2026-05-31 21:07:29

Label at a glance#

ProductDobutamine
Active ingredientDOBUTAMINE HYDROCHLORIDE
Label structure12 sections

Indications and uses

Dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short‑term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. Whether given...

Dosage and administration

Note - Do not add dobutamine to 5% Sodium Bicarbonate Injection or to any other strongly alkaline solution. Because of potential physical incompatibilities, it is recommended that dobutamine not be mixed with other drugs in the same solution. Dobutamine should not be used in conjunction with other agents or diluents containing both sodium bisulfite and ethanol. At the time of administration, dobutamine must be fur...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Dobutamine Injection USP is (±)-4-[2-[[3-(p-Hydroxyphenyl)-1-methylpropyl]amino]ethyl]-pyrocatechol hydrochloride. It is a synthetic catecholamine.

structure
structure

Molecular Formula: C18H23NO3•HCl

Molecular Weight: 337.84

The clinical formulation is supplied in a sterile form for intravenous use only. Each mL contains: dobutamine hydrochloride, equivalent to 12.5 mg (41.5 µmol) dobutamine; sodium metabisulfite 0.26 mg, and water for injection, q.s. Hydrochloric acid and/or sodium hydroxide may have been added during manufacture to adjust the pH (2.5 to 5.5).

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the ß receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. It does not cause the release of endogenous norepinephrine, as does dopamine. In animal studies, dobutamine produces less increase in heart rate and less decrease in peripheral vascular resistance for a given inotropic effect than does isoproterenol.

In patients with depressed cardiac function, both dobutamine and isoproterenol increase the cardiac output to a similar degree. In the case of dobutamine, this increase is usually not accompanied by marked increases in heart rate (although tachycardia is occasionally observed), and the cardiac stroke volume is usually increased. In contrast, isoproterenol increases the cardiac index primarily by increasing the heart rate while stroke volume changes little or declines.

Facilitation of atrioventricular conduction has been observed in human electrophysiologic studies and in patients with atrial fibrillation.

Systemic vascular resistance is usually decreased with administration of dobutamine. Occasionally, minimum vasoconstriction has been observed.

Most clinical experience with dobutamine is short-term–not more than several hours in duration. In the limited number of patients who were studied for 24, 48, and 72 hours, a persistent increase in cardiac output occurred in some, whereas output returned toward baseline values in others.

The onset of action of dobutamine is within 1 to 2 minutes; however, as much as 10 minutes may be required to obtain the peak effect of a particular infusion rate.

The plasma half-life of dobutamine in humans is 2 minutes. The principal routes of metabolism are methylation of the catechol and conjugation. In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine. The 3-O-methyl derivative of dobutamine is inactive.

Alteration of synaptic concentrations of catecholamines with either reserpine or tricyclic antidepressants does not alter the actions of dobutamine in animals, which indicates that the actions of dobutamine are not dependent on presynaptic mechanisms.

The effective infusion rate of dobutamine varies widely from patient to patient, and titration is always necessary (see DOSAGE AND ADMINISTRATION). At least in pediatric patients, dobutamine-induced increases in cardiac output and systemic pressure are generally seen, in any given patient, at lower infusion rates than those that cause substantial tachycardia (see PRECAUTIONS, Pediatric Use).

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short‑term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions.

Whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-AMP-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. In controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-AMP-dependent inotropes were consistently associated with increased risk of hospitalization and death. Patients with NYHA Class IV symptoms appeared to be at particular risk.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Dobutamine is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine.

WARNINGS

WARNINGS SECTION

Increase in Heart Rate or Blood Pressure

SPL UNCLASSIFIED SECTION

Dobutamine may cause a marked increase in heart rate or blood pressure, especially systolic pressure. Approximately 10% of adult patients in clinical studies have had rate increases of 30 beats/minute or more, and about 7.5% have had a 50 mm Hg or greater increase in systolic pressure. Usually, reduction of dosage promptly reverses these effects. Because dobutamine facilitates atrioventricular conduction, patients with atrial fibrillation are at risk of developing rapid ventricular response. In patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine. Patients with preexisting hypertension appear to face an increased risk of developing an exaggerated pressor response.

Ectopic Activity

SPL UNCLASSIFIED SECTION

Dobutamine may precipitate or exacerbate ventricular ectopic activity, but it rarely has caused ventricular tachycardia.

Hypersensitivity

SPL UNCLASSIFIED SECTION

Reactions suggestive of hypersensitivity associated with administration of dobutamine including skin rash, fever, eosinophilia, and bronchospasm, have been reported occasionally.

SPL UNCLASSIFIED SECTION

Dobutamine contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

  1. During the administration of dobutamine, as with any adrenergic agent, ECG and blood pressure should be continuously monitored. In addition, pulmonary wedge pressure and cardiac output should be monitored whenever possible to aid in the safe and effective infusion of dobutamine.
  2. Hypovolemia should be corrected with suitable volume expanders before treatment with dobutamine is instituted.
  3. No improvement may be observed in the presence of marked mechanical obstruction, such as severe valvular aortic stenosis.

Usage Following Acute Myocardial Infarction

SPL UNCLASSIFIED SECTION

Clinical experience with dobutamine following myocardial infarction has been insufficient to establish the safety of the drug for this use. There is concern that any agent that increases contractile force and heart rate may increase the size of an infarction by intensifying ischemia, but it is not known whether dobutamine does so.

Laboratory Tests

SPL UNCLASSIFIED SECTION

Dobutamine, like other ß2-agonists, can produce a mild reduction in serum potassium concentration, rarely to hypokalemic levels. Accordingly, consideration should be given to monitoring serum potassium.

Drug Interactions

DRUG INTERACTIONS SECTION

Animal studies indicate that dobutamine may be ineffective if the patient has recently received a ß-blocking drug. In such a case, the peripheral vascular resistance may increase.

Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.

There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Studies to evaluate the carcinogenic or mutagenic potential of dobutamine, or its potential to affect fertility, have not been conducted.

Pregnancy-Teratogenic Effects-Pregnancy Category B

PREGNANCY SECTION

Reproduction studies performed in rats at doses up to the normal human dose (10 mcg/kg/min for 24 h, total daily dose of 14.4 mg/kg), and in rabbits at doses up to twice the normal human dose, have revealed no evidence of harm to the fetus due to dobutamine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Labor and Delivery

LABOR & DELIVERY SECTION

The effect of dobutamine on labor and delivery is unknown.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when dobutamine is administered to a nursing woman. If a mother requires dobutamine treatment, breastfeeding should be discontinued for the duration of the treatment.

Pediatric Use

PEDIATRIC USE SECTION

Dobutamine has been shown to increase cardiac output and systemic pressure in pediatric patients of every age group. In premature neonates, however, dobutamine is less effective than dopamine in raising systemic blood pressure without causing undue tachycardia, and dobutamine has not been shown to provide any added benefit when given to such infants already receiving optimal infusions of dopamine.

Geriatric Use

GERIATRIC USE SECTION

Of the 1893 patients in clinical studies who were treated with dobutamine, 930 (49.1%) were 65 and older. No overall differences in safety or effectiveness were observed between these and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Increased Heart Rate, Blood Pressure, and Ventricular Ectopic Activity

SPL UNCLASSIFIED SECTION

A 10- to 20-mm increase in systolic blood pressure and an increase in heart rate of 5 to 15 beats/minute have been noted in most patients (see WARNINGS regarding exaggerated chronotropic and pressor effects). Approximately 5% of adult patients have had increased premature ventricular beats during infusions. These effects are dose related.

Hypotension

SPL UNCLASSIFIED SECTION

Precipitous decreases in blood pressure have occasionally been described in association with dobutamine therapy. Decreasing the dose or discontinuing the infusion typically results in rapid return of blood pressure to baseline values. In rare cases, however, intervention may be required and reversibility may not be immediate.

Reactions at Sites of Intravenous Infusion

SPL UNCLASSIFIED SECTION

Phlebitis has occasionally been reported. Local inflammatory changes have been described following inadvertent infiltration. Isolated cases of cutaneous necrosis (destruction of skin tissue) have been reported.

Miscellaneous Uncommon Effects

SPL UNCLASSIFIED SECTION

The following adverse effects have been reported in 1% to 3% of adult patients: nausea, headache, anginal pain, nonspecific chest pain, palpitations, and shortness of breath.

Isolated cases of thrombocytopenia have been reported.

Administration of dobutamine, like other catecholamines, can produce a mild reduction in serum potassium concentration, rarely to hypokalemic levels (see PRECAUTIONS).

OVERDOSAGE

OVERDOSAGE SECTION

Overdoses of dobutamine have been reported rarely. The following is provided to serve as a guide if such an overdose is encountered.

Signs and Symptoms- Toxicity from dobutamine is usually due to excessive cardiac ß-receptor stimulation. The duration of action of dobutamine is generally short (T1/2= 2 minutes) because it is rapidly metabolized by catechol-0-methyltranferase. The symptoms of toxicity may include anorexia, nausea, vomiting, tremor, anxiety, palpitations, headache, shortness of breath, and anginal and nonspecific chest pain. The positive inotropic and chronotropic effects of dobutamine on the myocardium may cause hypertension, tachyarrhythmias, myocardial ischemia, and ventricular fibrillation. Hypotension may result from vasodilation.

Treatment- To obtain up-to-date information about the treatment of overdose, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the Physicians’ Desk Reference (PDR). In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in your patient.

The initial actions to be taken in a dobutamine overdose are discontinuing administration, establishing an airway, and ensuring oxygenation and ventilation. Resuscitative measures should be initiated promptly. Severe ventricular tachyarrhythmias may be successfully treated with propranolol or lidocaine. Hypertension usually responds to a reduction in dose or discontinuation of therapy.

Protect the patient’s airway and support ventilation and perfusion. If needed, meticulously monitor and maintain, within acceptable limits, the patient’s vital signs, blood gases, serum electrolytes, etc.

If the product is ingested, unpredictable absorption may occur from the mouth and the gastrointestinal tract. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient’s airway when employing gastric emptying or charcoal.

Forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an overdose of dobutamine.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Note- Do not add dobutamine to 5% Sodium Bicarbonate Injection or to any other strongly alkaline solution. Because of potential physical incompatibilities, it is recommended that dobutamine not be mixed with other drugs in the same solution. Dobutamine should not be used in conjunction with other agents or diluents containing both sodium bisulfite and ethanol.

Preparation and Stability

SPL UNCLASSIFIED SECTION

At the time of administration, dobutamine must be further diluted in an IV container to at least a 50 mL solution using one of the following intravenous solutions as a diluent: 5% Dextrose Injection, 5% Dextrose and 0.45% Sodium Chloride Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, 10% Dextrose Injection, Isolyte® M with 5% Dextrose Injection, Lactated Ringer’s Injection, 5% Dextrose in Lactated Ringer’s Injection, Normosol®-M in D5-W, 20% Osmitrol® in Water for Injection, 0.9% Sodium Chloride Injection, or Sodium Lactate Injection. Intravenous solutions should be used within 24 hours.

HOW SUPPLIED

HOW SUPPLIED SECTION

Dobutamine Injection USP, 20 mL single dose vial contains dobutamine hydrochloride, equivalent to 250 mg dobutamine per 20 mL; ten vials per carton. NDC 0143-9141-10.

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Manufactured by:

HIKMA FARMACÊUTICA (PORTUGAL), S.A.

Estrada do Rio da Mó, 8, 8A e 8B – Fervença – 2705-906 Terrugem SNT, PORTUGAL

Distributed by:

Hikma Pharmaceuticals USA Inc.

Berkeley Heights, NJ 07922

April 2024                                                                                                             PIN612-WES/2

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0143-9141-01 Rx only

DOBUTamine
Injection, USP

250 mg per 20 mL (12.5 mg/mL)
For Intravenous Use ONLY
Must be diluted prior to use
Use within 24 hours after dilution
20 mL Single-Dose Vial 

label
label

NDC 0143-9141-10 Rx only

DOBUTamine
Injection, USP

250 mg per 20 mL (12.5 mg/mL)
For Intravenous Use ONLY
Must be diluted prior to use
Use within 24 hours after dilution
10 x 20 mL Single-Dose Vials 

cartoncarton

SERIALIZATION IMAGE

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

serialization imageserialization image

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1812168DOBUTamine 250 MG in 20 ML InjectionPSN6
181216820 ML dobutamine 12.5 MG/ML InjectionSCD6
1812168dobutamine (as dobutamine HCl) 250 MG per 20 ML InjectionSY6
1812168dobutamine 250 MG per 20 ML InjectionSY6

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
DOBUTAMINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
c061d745-4e41-be68-87e9-bad2cb726830Product name220240208
020518de-5dfd-f3a9-9c93-8015dad30497Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0143-9141-10Dobutamine20 mL in 1 VIALINJECTION, SOLUTION206
0143-9141-10Dobutamine10 in 1 CARTONINJECTION, SOLUTION106

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0143-9141DOBUTAMINE INJECTION, SOLUTION [HIKMA PHARMACEUTICALS USA INC.]6Current NDC, 2 package rows20240711_74ba9408-17d3-48ac-be0b-a4fee9e7a1a5.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0143-9141-10ML - Milliliter0143-91414e90dd8a-637d-4a9b-af94-da87c4543c6f12023-07-06

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0143-91410143-9141-10

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A074277-001DOBUTAMINE HYDROCHLORIDEDOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A074277-001AP

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31d4dbc9d85df4…
2026-10-15 13:18:302026-09A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31c2088c7a36db…
2026-09-14 22:38:342026-08A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-3184e616aacf4f…
2026-08-18 06:07:402026-07A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-3131067a03dcf5…
2025-08-23 18:47 UTC2025-08A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-316a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-3103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-312680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-315bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-3179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-311e350fbaab3a…
2024-05-31 18:47 UTC2024-05A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-318072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-315c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-315d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-314b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-3174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-3187673890dc5c…
2021-03-12 10:30 UTC2021-03A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-315aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-318869cabd3fbd…
2020-11-12 02:37 UTC2020-11A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31c0c555d07b60…
2019-12-14 00:12 UTC2019-12A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-313f01610625f2…
2019-09-15 20:21 UTC2019-09A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31b00525d2431f…
2019-07-19 19:46 UTC2019-07A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-316a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-311c564ffb4f44…
2023-12-20 04:57 UTC2023-12A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-319b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-313f0d92c62455…
2023-05-13 08:27 UTC2023-05A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-31053a50430f4f…
2023-01-26 05:58 UTC2023-01A074277-001DOBUTAMINE HYDROCHLORIDEEQ 12.5MG BASE/MLINJECTABLE / INJECTIONAP1994-10-313bdfa0b2c4d7…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A074277-001AP1d4dbc9d85df4…
2026-10-15 13:18:302026-09A074277-001AP1c2088c7a36db…
2026-09-14 22:38:342026-08A074277-001AP184e616aacf4f…
2026-08-18 06:07:402026-07A074277-001AP1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A074277-001AP1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A074277-001AP131067a03dcf5…
2025-08-23 18:47 UTC2025-08A074277-001AP16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A074277-001AP1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A074277-001AP1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A074277-001AP103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A074277-001AP12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A074277-001AP15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A074277-001AP1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A074277-001AP1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A074277-001AP179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A074277-001AP1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A074277-001AP11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A074277-001AP18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A074277-001AP15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A074277-001AP15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A074277-001AP14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A074277-001AP174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A074277-001AP1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A074277-001AP1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A074277-001AP187673890dc5c…
2021-03-12 10:30 UTC2021-03A074277-001AP15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A074277-001AP18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A074277-001AP1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A074277-001AP13f01610625f2…
2019-09-15 20:21 UTC2019-09A074277-001AP1b00525d2431f…
2019-07-19 19:46 UTC2019-07A074277-001AP1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A074277-001AP16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A074277-001AP11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A074277-001AP1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A074277-001AP1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A074277-001AP19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A074277-001AP1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A074277-001AP13f0d92c62455…
2023-05-13 08:27 UTC2023-05A074277-001AP1053a50430f4f…
2023-01-26 05:58 UTC2023-01A074277-001AP13bdfa0b2c4d7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
DobutamineDOBUTAMINEHikma Pharmaceuticals USA Inc.74ba9408-17d3-48ac-be0b-a4fee9e7a1a52024-07-02Warnings, Adverse reactionsExact identifier
ndc (package): 0143-9141-10
ndc (product): 0143-9141
ndc11 (package): 00143914110
spl id: b0a40444-634c-4eb0-a861-fe9e21e02552
spl set id: 74ba9408-17d3-48ac-be0b-a4fee9e7a1a5

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.